Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Payvar, C. Orlandi, W. Stough, U. Elkayam, J. Ouyang, S. Casscells, M. Gheorghiade (2006)
Comparison of 60-day mortality in hospitalized heart failure patients with versus without hypothermia.The American journal of cardiology, 98 11
J. Udelson, M. Bilsker, P. Hauptman, R. Sequeira, I. Thomas, T. O'Brien, C. Zimmer, C. Orlandi, M. Konstam (2011)
A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.Journal of cardiac failure, 17 12
Hyun Song, Mi-Jeong Kim, C. Chung, S. Choo, M. Song, Jong-Min Song, D. Kang, Jae-Won Lee, Jae-Kwan Song (2009)
Factors associated with development of late significant tricuspid regurgitation after successful left-sided valve surgeryHeart, 95
K. Chan, M. Zakkar, Emre Amirak, P. Punjabi (2009)
Tricuspid valve disease: pathophysiology and optimal management.Progress in cardiovascular diseases, 51 6
L. Gargani, Philip Schmidt, M. Gheorghiade (2011)
Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretionExpert Review of Cardiovascular Therapy, 9
Y. Ikeda, T. Inomata, Yuichiro Iida, T. Nabeta, Miwa Iwamoto, Syunsuke Ishii, Takanori Sato, T. Naruke, Toshimi Koitabashi, S. Niwano (2013)
The vasopressin V2-receptor antagonist, tolvaptan, can not only induce aquaresis but also enhance natriuresis in heart failure patients refractory to loop diureticsEuropean Heart Journal, 34
C. Izumi (2015)
Tricuspid regurgitation following left-sided valve surgery: echocardiographic evaluation and optimal timing of surgical treatmentJournal of Echocardiography, 13
A. Matsunaga, C. Duran (2005)
Progression of Tricuspid Regurgitation After Repaired Functional Ischemic Mitral RegurgitationCirculation, 112
M. Gheorghiade, W. Gattis, C. O'connor, K. Adams, U. Elkayam, Alejandro Barbagelata, J. Ghali, R. Benza, F. Mcgrew, M. Klapholz, J. Ouyang, C. Orlandi (2004)
Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized with Worsening Heart Failure: A Randomized Controlled TrialJAMA, 291
T. Niwa, K. Waseda, Tomofumi Mizuno, Y. Nakano, Kentaro Mukai, Hirokazu Wakabayashi, A. Watanabe, H. Ando, H. Takashima, T. Amano (2017)
Predictability of tricuspid annular plane systolic excursion for the effectiveness of tolvaptan in patients with heart failureJournal of Echocardiography, 15
L. Abello, A. Klein, T. Marwick, E. Nowicki, J. Rajeswaran, S. Puwanant, E. Blackstone, G. Pettersson (2013)
Understanding right ventricular dysfunction and functional tricuspid regurgitation accompanying mitral valve disease.The Journal of thoracic and cardiovascular surgery, 145 5
M. Konstam, M. Gheorghiade, J. Burnett, L. Grinfeld, A. Maggioni, K. Swedberg, J. Udelson, F. Zannad, T. Cook, J. Ouyang, C. Zimmer, C. Orlandi (2007)
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.JAMA, 297 12
Hilman Amin, Siska Danny (2016)
Tolvaptan: A Novel Diuretic in Heart Failure ManagementThe Journal of Tehran University Heart Center, 11
Yasser Rodriguez, J. Mesa, E. Arguelles, R. Carrillo (2013)
Tricuspid Insufficiency after Laser Lead ExtractionPacing and Clinical Electrophysiology, 36
K. Kinugawa, N. Sato, T. Inomata, Toshiyuki Shimakawa, Noriaki Iwatake, K. Mizuguchi (2014)
Efficacy and safety of tolvaptan in heart failure patients with volume overload.Circulation journal : official journal of the Japanese Circulation Society, 78 4
P. Forfia, M. Fisher, S. Mathai, T. Housten-Harris, A. Hemnes, B. Borlaug, Elzbieta Chamera, M. Corretti, H. Champion, T. Abraham, R. Girgis, P. Hassoun (2006)
Tricuspid annular displacement predicts survival in pulmonary hypertension.American journal of respiratory and critical care medicine, 174 9
H. Takano, M. Hiramatsu, H. Kida, Mitsuru Uenoyama, K. Horiguchi, Takashi Yamauchi, K. Kin, Y. Shirakawa, M. Kaneko, T. Daimon (2016)
Severe tricuspid regurgitation after mitral valve surgery: the risk factors and results of the aggressive application of prophylactic tricuspid valve repairSurgery Today, 47
R. Wong, Z. Abrahams, M. Hanna, Joseph Pangrace, G. Gonzalez-Stawinski, R. Starling, David Taylor (2008)
Tricuspid regurgitation after cardiac transplantation: an old problem revisited.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 27 3
Toshiki Miyazaki, H. Fujiki, Y. Yamamura, Shigeki Nakamura, Toyoki Mori (2007)
Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.Cardiovascular drug reviews, 25 1
Satoshi Suzuki, A. Yoshihisa, T. Yamaki, Koichi Sugimoto, H. Kunii, K. Nakazato, Y. Abe, Tomiyoshi Saito, T. Ohwada, Hitoshi Suzuki, Shu‐ichi Saitoh, I. Kubota, Y. Takeishi (2013)
Acute heart failure volume control multicenter randomized (AVCMA) trial: Comparison of tolvaptan and carperitideJournal of Clinical Pharmacology, 53
M. Gheorghiade, I. Niazi, J. Ouyang, F. Czerwiec, J. Kambayashi, M. Zampino, C. Orlandi (2003)
Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized TrialCirculation: Journal of the American Heart Association, 107
Objectives Our objective was to explore the effects of tolvaptan as a new therapeutic approach in patients with right heart failure with tricuspid insufficiency (TI). Methods This prospective, multicenter, non-randomized controlled pilot study enrolled patients (N = 40) with TI from the Shanghai Chest Hospital and Shanghai Tongren Hospital who fulfilled inclusion criteria between March 2015 and June 2016. Participants were assigned to receive either tolvaptan combined with torasemide (n = 20) or torasemide monotherapy (n = 20; control group). The primary endpoints were changes in patient weight and in tricuspid annular plane systolic excur- sion (TAPSE) after 10 days of treatment. The secondary endpoints included net fluid balance and cardiac functions before and after medication from the first to the tenth day of treatment. Safety was evaluated by monitoring adverse and serious adverse events. Results TAPSE significantly increased in the tolvaptan group compared with the control group after 10 days of medication (P = 0.029). Daily weight losses in the tolvaptan group signic fi antly increased as the time of treatment increased (time × group, P = 0.022). Recovery to New York Heart Association (NYHA) grade I occurred 4 days earlier in the tolvaptan group. In addi- tion, the net fluid
American Journal of Cardiovascular Drugs – Springer Journals
Published: Sep 25, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.